Latest Statin Stories
Bernstein Liebhard LLP, which is currently representing clients in the federal Lipitor proceeding, reports that the Court has granted Pfizer’s Motion, and has dismissed four individual Lipitor
Court records updated on March 16, 2015 reflect the filing of nearly 2,100 Lipitor lawsuits in the U.S.
Submission of Application in Japan Marks an Important Milestone in Strategic Partnership With Amgen Astellas BioPharma THOUSAND OAKS, Calif., March 20, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
Study from NYU Langone Medical Center Shows that Nutrition is Rated as Important as Statins for Preventing Heart Disease NEW YORK, March 16, 2015 /PRNewswire-USNewswire/ -- Most physicians
- Robust and consistent LDL-C lowering demonstrated with Praluent(TM) in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date - PARIS and TARRYTOWN, N.Y., March 15,
Analysis From Prespecified Exploratory Endpoints Presented in Late-Breaking Session at ACC.15 Showed Repatha Plus Standard of Care Lowered Cardiovascular Events THOUSAND OAKS, Calif., March
Robust and consistent LDL-C lowering demonstrated with Praluent(TM) in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date TARRYTOWN, N.Y.
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
In a nested-case control study of individuals living in the UK, a part of the world with a relatively low incidence of liver cancer, statin use is associated with a decreased risk of liver cancer,